MedPath

Shah, Nirmish

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 3
1 (50.0%)

AB1 in Adult Patients with Sickle Cell Disease (SCD)

Phase 1
Terminated
Conditions
Sickle Cell Disease
Interventions
First Posted Date
2022-03-02
Last Posted Date
2024-12-04
Lead Sponsor
Nirmish Shah
Target Recruit Count
16
Registration Number
NCT05261711
Locations
🇺🇸

Augusta University Medical Center, Augusta, Georgia, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

East Carolina University, Greenville, North Carolina, United States

Apixaban in Patients With Sickle Cell Disease

Phase 3
Terminated
Conditions
Sickle Cell Disease
Vaso-occlusive Crisis
Reduction in Hospitalizations
Interventions
Drug: Placebo
First Posted Date
2014-07-01
Last Posted Date
2020-03-11
Lead Sponsor
Nirmish Shah
Target Recruit Count
16
Registration Number
NCT02179177
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.